MedTrace Logo

Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study

NCT01342497 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-12-23

No results posted yet for this study

Summary

The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.

Conditions

  • Diabetic Foot Ulcer

Interventions

DRUG

isoniazide

Tablets, dosing 3 times daily, 12 weeks

DRUG

placebo

tablets, dosing 3 times daily, 12 weeks

Sponsors & Collaborators

  • Bridge BioResearch Ltd.

    lead INDUSTRY

Principal Investigators

  • Andrew J Boulton, Professor · Manchester Royal Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01342497 on ClinicalTrials.gov